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Abstract 
Nose to brain delivery and nanotechnology are the combination of innovative strategies for 
molecules to reach the brain and to bypass blood brain barriers. In this work we investigated the fate 
of two rhodamine B labeled polymeric nanoparticles (Z-ave<250 nm) of opposite surface charge in 
different areas of the brain after intranasal administration in rats. A preliminary screening was 
carried out to select the suitable positive (chitosan/poly-l-lactide-co-glycolide) nanocarrier through 
Photon Correlation Spectroscopy and Turbiscan. Physico-chemical and technological 
characterizations of poly-l-lactide-co-glycolide (negative) and chitosan/poly-l-lactide-co-glycolide 
(positive) fluorescent labeled nanoparticles were performed. The animals were allocated to three 
groups receiving negative and positive polymeric nanoparticles via single intranasal administration 
or no treatment. The localization of both nanocarriers in different brain areas was detected using 
fluorescent microscopy. Our data revealed that both nanocarriers reach the brain and are able to 
persist in the brain up to 48 h after intranasal administration. Surface charge influenced the involved 
pathways in their translocation from the nasal cavity to the central nervous system. The positive 
charge of nanoparticles slows down brain reaching and the trigeminal pathway is involved, while 
the olfactory pathway may be responsible for the transport of negatively charged nanoparticles, and 
systemic pathways are not excluded. 
 
 
 
 
Keywords: intranasal delivery, chitosan nanoparticles, PLGA, brain, fluorescent microscopy, in vivo 
study, rats. 
 
 
 
3 
 
Abbreviations: 
BBB- Blood Brain Barrier  
CNS- Central Nervous System  
CS- Chitosan  
CSF-Cerebral spinal fluid  
DSC- Differential Scanning Calorimetry 
%DTE- drug targeting efficiency percentage 
%DTP- direct transport percentage 
E.E. - Encapsulation Efficiency 
FDA- Food and Drug Administration 
GRAS- Generally Recognized As Safe 
IN- IntraNasal   
LMW- Low Molecular Weight  
MPS- Mononuclear phagocyte system 
N2B- Nose to Brain  
NPA- PLGA NPs  
NPBC–chitosan/PLGA NPs (NPBC3; NPBC5; NPBC10; NPBC20) 
NPs- nanoparticles  
P.D.I.-polidispersity index  
PBS- Phosphate Buffer Solution  
PCS- Photon Correlation Spectroscopy  
PFA-Paraformaldehyde 
PLA- Poly-lactide 
PLGA- Poly-lactide-co-glycolide 
SEM- Scanning electron microscopy 
TSI- Turbiscan stability index 
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ZP- Zeta potential values  
ΔH- enthalpy changes  
ΔBS- Delta Backscattering 
ΔT- Delta Transmission 
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Introduction 
The intranasal (IN) route is commonly used for local disease treatments and systemic delivery of 
drugs; furthermore, this route is considered to be a potential alternative way of administrating drugs 
to the brain, specifically to bypass the blood–brain barrier (BBB). The nose to brain route serves as 
a direct delivery route of molecules to the brain (Chapman et al., 2013). Novel delivery devices 
have been developed for this purpose (ViaNase IDTM; OptiNose; POD-Precision Olfactory 
Delivery-device) (Djupesland et al., 2014). These devices can transport nanosuspensions or 
molecules in solution to specific regions of the nasal cavity in man (olfactory region).  
IN administration is a non-invasive method and could represent an alternative strategy for drugs 
commonly administered orally or intravenously and that have difficulty moving across the BBB 
(Chapman et al., 2013; Tosi et al., 2016). As reported by Kozlovskaya et al. (2014), several papers 
describe drug accumulation in the brain following IN application of the drug solution or suspension, 
but some free drugs could achieve low therapeutic concentration in the brain using this route, as 
previously demonstrated (Piazza et al., 2014, Meredith et al., 2015, Zhang et al, 2014). Among the 
different types of drug carriers, due to their mean size, nanoparticles (NPs) used for drug delivery, 
may increase the therapeutic dose of drugs in the brain when administered intranasally. In fact, 
these carriers could protect against local enzymatic degradation, increase IN residence time by 
avoiding mucociliary clearance, and possibly achieve prolonged release at the target site. Shadab et 
al. (2014) have shown that NPs transported drugs into the brain suggesting a direct transport to this 
site that bypasses the BBB (Shadab et al., 2014, Kozlovskaya et al., 2014). 
The selection of polymers requires a preliminary evaluation related to the site of administration and 
the hypothetical fate of NPs (Kumari et al., 2010). Chitosan (CS) NPs are the most commonly 
investigated nanocarriers for nose to brain delivery and are suitable for the transport of hydrophilic 
molecules (Casettari et al., 2014). CS is a natural polysaccharide that is capable of increasing the 
NPs residence time in the nares due to its mucoadhesive properties and this polymer may also act as 
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a penetration enhancer; furthermore, it is generally recognized as safe material (GRAS) (Charlton et 
al., 2007; Duttagupta et al., 2015). Currently, hybrid nanocarriers are prepared using two different 
types of polymers, and chitosan could be used to confer a positive charge to a PLGA nanoparticle 
surface (Bharali et al. 2015). Poly-lactide-co-glycolide (PLGA), co-polymer of poly-lactide (PLA), 
is a suitable material to prepare NPs for lipophilic or amphiphilic molecules for its tunable physico-
chemical properties and it is a Food and Drug Administration (FDA) approved polymer (Kapoor et 
al., 2015). 
In our previous in vitro study, we demonstrated the influence of surface charge on the uptake of 
rhodamine B labeled NPs via olfactory glial cells (Musumeci et al., 2014), according to other 
authors for a different type of cells.  
The proof of concept of nose to brain delivery of NPs is claimed by different authors; for example, 
some described toxicological effects in the brain because of inhaled ultrafine particles (van Berlo et 
al., 2014). Others demonstrated the nose to brain direct transport through the evaluation of the “drug 
targeting efficiency percentage (%DTE)” or “direct transport percentage (%DTP)” values or 
through in vivo behavioral studies. In particular, authors compared the results obtained after IN 
administration of the drug loaded NPs and other routes (Kozlovskaya et al., 2014; Phukan et al., 
2016). 
Despite the promising results, some questions have not been answered. First of all, is there a 
tropism for particular brain sub-regions after IN administration of NPs? If so, is this tropism 
influenced by anatomical-physiological conditions? Could surface properties of NPs influence the 
localization in different brain sub-regions? Literature data show that NPs reach the brain prevalently 
in the olfactory and/or trigeminal region after IN administration, but no correlation was made 
between these results and the surface properties of NPs investigated during a time course. 
In this work, we carried out in vivo studies on rats in order to correlate opposite surface (positive 
and negative) charges of the selected rhodamine B labeled NPs with the regional brain localization 
after IN administration up to 48 h. Chitosan-PLGA (poly(lactic-co-glycolic acid) NPs were selected 
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after a preliminary screening using photon correlation spectroscopy (PCS) and Turbiscan analyses. 
In vivo brain localization analyses were carried out in healthy rats after IN administration of PLGA 
and Chitosan-PLGA fluorescent NPs through fluorescent microscopy. 
Materials and methods 
Materials 
Low molecular weight (LMW: molecular weight is 50,000-190,000 daltons based on viscosity; 
viscosity 20-300 cps, deacetylation degree 75-85%) water-soluble chitosan derived from crab 
shells, Tween®80, rhodamine Band glacial acetic acid (d 1,049 g/ml a 25°C) were purchased from 
Sigma-Aldrich (Milan, Italy). Sodium sulfate, sodium hydroxide and all other chemicals were 
analytical grade, purchased from Analyticals, Carlo Erba. The polymer Resomer® 502 H poly-(D,L-
lactide-co-glycolide) (50:50, molecular weight is 30,000-60,000) were purchased from Boehringer 
Ingelheim Pharma GmbH&Co. KG (Boehringer Ingelheim, Germany). Ultrapure water was used 
throughout this study. For biological studies, we used adult male Wistar rats (200-250 gr b.w., 
Envigo s.r.l. - ex Harlan, Italy), Zoletil 100 and Dexdomitor anesthetics, paraformaldehyde and 
other chemicals from Sigma-Aldrich (Milan, Italy). 
 
PLGA nanoparticle preparation as negative surface charge nanocarriers 
PLGA NPs (NPA) were prepared using the solvent displacement method followed by polymer 
deposition as previously reported (Musumeci et al., 2013). Briefly, the chosen polymer (75 mg) was 
dissolved in acetone (20 ml). The organic phase was added drop by drop to a 40 ml water/ethanol 
solution (1:1, v/v) containing 0.5% (w/v) Tween® 80 under magnetic stirring, obtaining a milky 
colloidal suspension. The organic solvent was then evaporated off under high vacuum at 40° C. 
Fluorescent-labeled NPs were prepared by co-dissolving rhodamine B (5 µg/ml) with the polymer 
in the organic phase. The different formulations were purified through ultracentrifugation 
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(15000×g) for 1h at 10°C, using a Beckman (Fullerton, CA) J2-21 model centrifuge equipped with 
a Beckman JA-20.01 fixed-angle rotor. After washing, the obtained NPs were re-suspended in 5 ml 
of filtered water (0.22 µm Sartorius membrane filters). This procedure was repeated three times. 
The obtained samples were characterized according to mean size, size distribution and surface 
chemistry.  
Chitosan/PLGA nanoparticle preparation as surface charge positive nanocarriers 
Chitosan/PLGA NPs were prepared using the nanoprecipitation method, “In situ coating method”,as 
described by Sanna et al. (2012) with little modification (modified by Sanna et al., 2012). 
Chitosan/PLGA NPs, identified as NPBC, were prepared. The influence of the amount of polymer 
was evaluated on physico-chemical characteristics. Briefly, PLGA at different concentrations (3, 5, 
10, 20 mg/ml; respectively identified as NPBC3, NPBC5, NPBC10, NPBC20) was dissolved in 
acetone and was added dropwise into a chitosan (CS) solution (0.1% w/v solubilzed in acetic acid 
solution 0.1% v/v, 5 mL). The resulting milky colloidal suspension was evaporated at room 
temperature to remove a portion of the organic solvent (1 h). Then the organic solvent was 
evaporated off under high vacuum at 40°C. The different formulations were purified through 
ultracentrifugation (11000×g) for 1h at 8 °C, using a Beckman (Fullerton, CA) J2-21 model 
centrifuge equipped with a Beckman JA-20.01 fixed-angle rotor. After washing, the obtained NPs 
were re-suspended in 5 ml of filtered water (0.22 µm Sartorius membrane filters). This procedure 
was repeated three times. The obtained samples were characterized according to mean size, size 
distribution and surface chemistry. Also Turbiscan analysis was carried out. After the selection of 
the suitable nanosuspension (NPBC3), fluorescent-labeled Chitosan/PLGA NPs were prepared by 
co-dissolving rhodamine B (5 µg/mL) with the PLGA polymer in the organic phase.  
Particle size, size distribution and Zeta potential analyses 
The particle size and the polidispersity index (P.D.I.) of nanoaggregates were measured performing 
photon correlation spectroscopy (PCS) with a Zetasizer Nano S90 (Malvern Instruments, Malvern, 
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UK) at a detection angle of 90°, at 25°C with a 4mW He-Ne laser operating at 633 nm. Each value 
was measured in triplicate. The results are shown as mean ± standard deviation. The samples were 
analyzed using a disposable cuvette, “DTS 0012 Disposable sizing cuvette”, withdrawing 700 μl of 
suspension. The Zeta potential values (ZP), which reflect the electric charge on the particle surface, 
were determined at 25°C using the same equipment described previously. For the measurement, 
samples were diluted appropriately with ultra-purified water. 
Turbiscan study 
Turbiscan™ AGS (Formulaction, l’Union, France, a robot and a storage station integrated 
TurbiscanLAB) was used to examine the dispersion stability of NPs. This instrument allows for the 
use of a simple technique to observe reversible (creaming and sedimentation due to fluctuation on 
particle size and volume) and irreversible (coalescence and segregation due to particle size 
variation) destabilization phenomena in the sample. Turbiscan™AGS is useful to detect 
destabilization phenomena much earlier and also in a more simple way than other methods. Each 
suspension (15 mL) was placed in flat-bottomed cylindrical glass tubes, which were placed in the 
instrument and the transmission of light from the suspensions was then measured periodically (1h) 
along the height at room temperature and at 25 °C for up to 48 h. The sedimentation behavior of the 
suspensions was monitored by measuring the backscattering and monochromatic transmission near 
infrared (λ = 850/880 nm). The sedimentation rate was evaluated from the change in backscattering 
intensity at the top portion of the sample. 
 
Physico-chemical, morphological, calorimetric analyses and in vitro release study of labeled 
NPs 
Differential scanning calorimetric analysis 
A Mettler Toledo DSC 1 STARe system equipped with a PolyScience temperature controller 
(PolyScienceIllinois, USA) was used to perform calorimetric analyses. The detection system was a 
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HSS8 high sensitivity sensor (120 gold-gold/palladium-palladium thermocouples) and the ceramic 
sensor (Mettler Full Range; FRS5) with 56 thermocouples. The signal time constant was 18 s and 
the digital resolution of the measurement signal was less than 0.04 µW. Calorimetric resolution and 
sensitivity, determined through the TAWN test, is respectively 0.12 and 11.9. The sampling rate is 
50 values/second. The sensitivity was automatically chosen as the maximum possible through the 
calorimetric system, and the reference was an empty pan. The calorimetric system was calibrated, in 
temperature and enthalpy changes, by using indium by following the procedure of the DSC 1 
Mettler TA STARe instrument. NPs were sealed in an aluminum pan and submitted to DSC analysis 
to determinate the influence of coating on thermotropic parameters of NPs. Each sample was 
submitted to heating and cooling cycles in the temperature range 10-200 °C at a scanning rate of 
5°C/min (heating) and at a scanning rate of 10°C/min (cooling). Transition temperature and 
enthalpy changes (ΔH) were calculated from peak areas with the MettlerSTARe Evaluation software 
system (version 13.00) installed on Optiplex 3020 DELL. 
SEM analysis 
Scanning electron microscopy (SEM) was performed to evaluate the surface morphology of NPs 
using a SEM Philips mod 500. NP samples were dried for 24 h before the analysis. A small amount 
of NPs was stuck on a double-sided tape attached on a metallic sample stand, then coated, under 
argon atmosphere, with a thin layer of gold, using a POLARON E5100 SEM Coating Unit.  
In vitro release studies 
The in vitro release studies of rhodamine from PLGA NPs and chitosan/PLGA NPs were performed 
using cellulose membrane dialysis tubing (Spectra/Por® 3 Dialysis Membranes, MWCO 3.5kD, 
Flat width 18 mm, diameter 11.5 mm, Vol/Lg 1.1 ml/cm, Length 15 m/ 50 ft; Spectrum® 
Laboratories). The samples (1 ml) were enclosed in dialysis bags and incubated in 19 ml PBS (pH 
7.4; pH 5.8) with constant shaking, 100 rpm, in water bath at 37 ± 0.5 °C. At predetermined time 
intervals (1, 2, 3, 4, 5, 24, 48 h), a fixed volume of release medium was withdrawn and replaced 
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with an equivalent amount of release media. These samples were analyzed using UV 
spectrophotometry at rhodamine λ-max (555.2 nm in PBS pH7.4; and pH 5.8) (UV-VIS 1601 
spectrophotometer, Shimadzu Italia, Milan, Italy). Calibration curves for the quantitative evaluation 
of the probe were linear in the following ranges:(i) 3.24–0.66 µg/ml of rhodamine (r2 = 0.9984) for 
analyses in PBS pH 7.4; (ii) 7.05–0.56 µg/ml of rhodamine (r2 = 0.9991) for analyses in PBS pH 
5.8. 
In vivo experiments   
All the in vivo experiments were performed following the Guidelines for Animal Care and Use of 
the National Institutes of Health. The study was approved by Italian Ministry of Health (permit 
number 183). Two lots of fifteen adult male rats weighing 200-220g were acclimatized for one 
week before the study with free access to water and food. The rats were anaesthetized with Zoletil 
100 (100 mg/kg, i.p.) and placed on a heated working surface to prevent hypothermia. Both lots 
respectively received an IN injection of 50 μl of positive or negative rhodamine labeled NPs. The 
IN injection was given according to Dyer et al. (2002). Briefly, the rats were placed in a supine 
position and 25 μl were administered in each opening nostril (alternating) using a microliter syringe 
attached, via a needle, to a short polyethylene tubing, inserted approximately 0.7 cm into one 
nostril. The procedure was performed slowly in about 1 minute. Each lot was divided into three 
groups of five rats each and the three groups were sacrificed at different time intervals (8, 24, 48 h) 
and no treat. A control group of five rats was treated with 25 μl of rhodamine B solution in each 
nostril. The animals were deeply anaesthetized with an intraperitoneal injection of Zoletil 100 (100 
mg/kg) and Dexdomitor (20-30 μg/Kg) and perfused trancardially with a 4% paraformaldehyde 
(PFA) solution in 0.1 M phosphate buffer solution (PBS, pH 7.4). The brains were removed, post-
fixed overnight in the same 4% PFA and then transferred into a 30% sucrose cryoprotective solution 
in PBS at 4°C for2-3 days. Serial 25 µm frozen sections of the brain were cut along the sagittal 
plane, mounted on slides, and air-dried. The fluorescence was examined on a fluorescence 
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microscope (Nikon Eclipse 80i) equipped with filters for the visualization of rhodamine (excitation 
530– 560 nm). Images were captured using a digital camera (Nikon) and adjusted for contrast with 
Adobe Photoshop without compromising data integrity. 
Results  
The hydrodynamic diameter is one of the most important parameters for the development of 
suitable nanocarriers for nose to brain (N2B) delivery. Only small particles can be transported to the 
brain via the olfactory or the trigeminal nerves (Mistry et al., 2009, Mistry et al. 2015). PLGA was 
chosen as a primary polymer to prepare negative surface nanoparticles. PLGA is widely used as a 
suitable polymer to prepare nanocarriers and it is a well-known material for our research group (Li 
Volti et al., 2012; Vicari et al., 2008). Chitosan was chosen to modify PLGA nanoparticles and to 
obtain positive nanoparticles in order to compare two nanosystems having opposite surface charge. 
The influence of different PLGA/CS ratios on the physico-chemical characteristics of colloidal 
carriers was evaluated to select the nanosuspension with the most suitable properties in order to 
perform in vivo studies for N2B delivery. 
Microparticles could release molecules in the nasal cavity determining diffusion of free molecules 
to the brain. Migration may occur through the nasal olfactory and respiratory mucosa, as well as 
through the capillaries, lymphatic, and cerebrospinal fluid present in the nasal mucosa (Rassuet al., 
2015). Once released in the nasal cavity, the free drug can be affected by biological environment 
degradation and the drug therapeutic concentration may consequently be achieved. Nanoparticles 
can be transported via olfactory epithelium and/or trigeminal nerve system and the encapsulated 
molecule can be released directly to the brain (Kozlovskaya et al., 2014; Mistry et al., 2015). 
The effect of polymer amount on mean size, surface properties and stability of CS/PLGANPs 
The nanoprecipitation method was successfully applied to prepare CS/PLGANPs. Nanocarriers 
were obtained through the precipitation of PLGA in the CS polyelectrolyte solution which 
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introduces positive charges on the NPs, allowing us to obtain NPs with a mean size ranging from 
200 to 800 nm and a polydispersity index ranging from 0.2 to 0.4. As shown in figure 1, only the 
formulation having the higher level of polymer produced a heterogeneous particle population. NPs 
smaller than 250 nm in diameter were obtained at a low polymer concentration (from 3 to 5 mg/ml). 
All the nanocarriers presented a positive charge about +70 mV and the values were not influenced 
by PLGA amount (data not reported). 
Figure 1 should be inserted here 
To support PCS results even Turbiscan analysis was performed. We determined the nano-dispersion 
stability as a function of PLGA amount. NPs were analyzed immediately after preparation with an 
appropriate dilution. Taking into account that the nanosuspensions were destabilized through a 
sedimentation and/or aggregation phenomenon, TSI (Turbiscan Stability Index) was examined. 
Figure 2A showed the TSI values for all the nanosuspensions at 25 ° for up to 48 h. The 
nanosuspension with the lowest polymer amount is the most stable nanoparticle formulation (lowest 
values of TSI). In figure 2B, ΔTransmission (ΔT) and Δ Backscattering (ΔBs) data showed no 
variations in the middle part of the graph, so no aggregation occurred. The variation at the bottom 
may represent a sedimentation phenomenon of a re-dispersible nanosuspension. All NPs appeared 
sufficiently stable for up to 48 according to the high values of zeta potential. 
Figure 2 should be inserted here 
The properties of positive and negative rhodamine labeled NPs 
We focused our attention on two types of polymeric NPs for in vivo studies, in order to investigate 
their fate in the sub-regions of the brain after IN administration in healthy rats.  
NPs were characterized using thermal analysis, which represents a useful technique to detect NP 
properties after the production process (Gill et al., 2010). DSC thermograms of the raw materials 
and selected NPs are shown in Figure 3. PLGA sample (C) presented a glass transition temperature 
(Tg) of about 40 °C. Chitosan (D) presented an exothermic peak at 40°C due to the loss of water 
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molecules. In the thermograms obtained through PLGA NPs (B) the vitreous transition is also 
present. After the addition of chitosan, the exothermic peak of NPBC3 (A) disappeared and the Tg is 
rather weak (Latif et al., 2015). 
Figure 3 should be inserted here 
As depicted in the SEM images (figure 4 A and B), both nanosuspensions are spherical and with 
smooth surfaces. While NPA appeared well separated, NPBC3 presented some aggregates 
confirming the different values of P.D.I.  
In figure 4 physico-chemical properties are also shown. Both nanosuspensions presented mean size 
≤ 230 nm (figure 4 C and D) with positive surface charge for CS/PLGA NPs and negative for PLGA 
NPs (figure 4 E and F). 
The mean size distribution (PDI), as also shown by SEM, highlight a more homogeneous particle 
population for NPA respect to NPBC3. 
Figure 4 should be inserted here 
Even a rhodamine in vitro release study was performed in order to evaluate that the fluorescence 
observed through microscopy analysis is due to the probe loaded into the nanocarriers and/or to the 
probe released from the nanocarriers (figure 1, supplementary data). As shown, 5% of rhodamine 
was released after 24 h; a slow and prolonged release was observed for up to 48 h where 15% of 
rhodamine was released (maximum in vivo experiment time).  
 
Sub-region localization in the rat brain of fluorescent labeled polymeric NPs 
The localization of negative surface charge (NPA) and positive surface charge (NPBC3) NPs were 
investigated in brain sub-regions at 8, 24 and 48 h after IN administration. We investigated the brain 
sub-regions in rats that are the principle targets for the different neurological diseases (figure 2, 
supplementary). The sections were prepared according to the sagittal illustration of the rat brain in 
15 
 
Paxinos and Watson (Paxinos, 1982). Preliminary study demonstrated that no or only very few cells 
presented fluorescence after 2 and 4 hours of the nasal administrations (data not reported).  
No fluorescence is depicted in non-treated brain rats (figure 5A) and slight and homogenous 
rhodamine distribution is shown in rat treated with rhodamine solution (figure 5B). The uptake of 
NPs in the brain was significantly increased 8-24 and 48 hours after IN administration and the 
labeled NPs were found in some brain areas. All NPs were prevalently localized in the cytosol of 
neural cells (figure 5C). NPs were also observed outside the cells, but were found with reduced 
frequency when compared to the level found in the cytosol. 
Figure 5 should be inserted here 
A summary of the labeling found in the various brain regions with negative and positive NPs was 
reported in Table 1.  
Table 1 should be inserted here 
The areas, where we found the NPs localized, are the following: Cerebral cortex, the frontal and 
parietal cortex, prevalently, while only a few NPs were found in the occipital cortex. The cerebral 
layers involved in NPs distribution were layer V and only a few in layers III, IV, VI and none in the 
superficial layers; Basal ganglia, in the caudate-putamen nucleus, prevalently; Hippocampus, in 
CA1-CA3 regions and in the granular layer of the dentate gyrus, few NPs were also observed in the 
entorhinal cortex and subiculum; Basal forebrain, the fluorescent label was observed in Piriform 
cortex and amigdaloid nuclei. In the Thalamus NPs were found in the reticular nucleus, central 
complex, anterior and dorsal nuclei; Mesencephalon, in the tegmental and pretectal nuclei. In the 
Cerebellum NPs were found in the Purkinje cell as well as in the cerebellar and vestibular nuclei; 
Myelencephalon, the reticular substantia, as well as spinal, trigeminal and facial nuclei. In the other 
brain sub-regions, here not mentioned, no or very scant negative and positive NPs were found (data 
not shown). The difference in fluorescence signals between the in vivo micrographs of the two type 
of NPs is a clear demonstration that is not due to the free marker.  
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Regarding the trend of each nanosuspension we could describe a localization time – dependent on 
the surface charge of NPs. In fact, after 8 h of IN administration a decrease in fluorescence for 
negative NPs from the rostral to caudal area was found. An opposite trend was observed after 48 h, 
where the caudal region showed a higher fluorescence compared to the caudal, while after 24h a 
uniform distribution in all the cerebral structures was found (figure 6). The localization of 
CS/PLGA NPs had a different trend compared to negative NPs (figure 7). Since we found a weak 
labeling in all areas after 8 h and 24 h of IN administration, except in the cerebral cortex where the 
signal was moderate after 24 h, only after 48 h did we observe an intense/moderate labeling in some 
cerebral structures.  
Figures 6 and 7 should be inserted here 
Discussion 
Preliminary screening is important to select the ideal carrier to perform an in vivo study. According 
to Sanna et al. (2012), the combination of PLGA with chitosan leads to an increase of NP mean size 
strictly correlated with the increment of PLGA concentration. As shown in figure 1, the increase in 
polymer concentrations significantly increases the mean particles size. This variable did not 
influence the surface charge values largely governed by chitosan adsorption on the surface of the 
NPs. In this work we demonstrate that a reduction of the ratio between PLGA and CS used for the 
preparation of NPs, allows for the formation of a nanocarrier with a positively charged surface and 
a mean size below 250 nm. A positive charge of NPBC NP series is due to the protonation of amine 
groups of CS, the possible electrostatic interaction with carboxylic groups of PLGA masking 
negative charges. Zeta potential is an important parameter because it allows for the prediction of 
physical stability and, according to the “electrostatic theory of mucoadhesion”, even nanosphere/IN 
mucoadhesion to increase residence time (Shaikh et al., 2011). The highest Zeta potential values, 
either positive or negative in absolute value, produce stable dispersions due to particle electrostatic 
repulsions. The electrostatic repulsions between particles with the same electrical charge prevent 
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particle aggregation. The highly positive Zeta potential has the potential to produce a formulation 
with good stability (Honary et al., 2013b). Turbiscan and PCS taken together allowed us to select 
the NPBC3 sample for the following investigations. NPBC NP series were stable against 
sedimentation, as evaluated by the Turbiscan analysis. NPBC3 demonstrated a good stability for the 
total duration of the experiment compared to the other samples, as elucidated by TSI values (figure 
2A). ΔT and ΔB data showed no variations in the middle part of the graph, which means there was 
no flocculation/aggregation of the sample, thus confirming its higher stability in terms of particle 
size. As previously observed by PCS, this phenomenon is correlated with high zeta potential value 
(Bru et al., 2004). NPBC3 nanosuspension is affected by the sedimentation process; in fact, the 
increase of backscattering level that occurred at the bottom indicates a decrease in the concentration 
of particles consecutive to the sediment formation. The obtained cake was easily re-dispersible 
(Dihang et al., 2005). 
NPBC3 was selected as the positive formulation to perform in vivo studies along with NPA 
(negative). The NP samples selected (NPA and NPBC3) were further characterized (figure 3 and 
figure 4). Figure 4 summarizes some physico-chemical properties of both nanocarriers. Slight 
morphological differences were observed between the two samples (figure 4, A and B). The 
aggregate particles observed through SEM are due to the dried process necessary to perform 
analyses. 
In order to detect the location/distribution in the brain, rhodamine was encapsulated into the 
nanocarriers as a fluorescent marker. Moreover, cellular uptake of both NPs was investigated. For 
both NPs the encapsulation efficiency (E.E.) of rhodamine was assessed and it resulted in ~10%. 
The selected nanocarriers showed a mean size < 250 nm and opposite surface charge.  
As previously reported by Mistry et al. (2015), there are three routes that allow NPs to achieve brain 
delivery after IN administration (systemic, olfactory and trigeminal pathway). We could consider 
nose to brain transport when the amount of NPs that reaches the brain through the systemic pathway 
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is negligible when compared to trigeminal and olfactory pathways. In the last two years, several 
authors have examined the influence of NP surface chemistry on the biological environment, in 
order to increase the therapeutic efficacy of NPs (Honary et al., 2013a; De Jong et al., 2008).  
However, there are relatively few studies that describe the influence of the surface charge of NPs on 
the localization in different brain sub-regions (rostral and/or caudal brain regions) during a time 
course after IN administration (Buchner et al., 1987). Knowing where and when NPs arrive in the 
brain is very important for drug delivery. Mechanisms by which NPs internalize and transport into 
the brain are poorly defined. The interaction of particles with cells is known to be strongly 
influenced by particle size, but little is known about the interdependent role that size, shape, and 
surface chemistry have on cellular internalization and intracellular trafficking of micro- and 
nanoparticles. 
NPs mean diameter affects their interactions with cells and determines the active or passive cellular 
internalization and intracellular localization. Once in the body NPs are selectively transported into 
and out of the cells via endocytosis and exocytosis mechanisms. Following exocytosis NPs may 
have the ability to pass through in vivo barriers and cause unpredicted biological effects. The mean 
size itself of particles can determine the pathway of intracellular entry (Shang et al., 2014). 
Different mechanisms of endocytosis can be involved, varying with the size of the transport vesicles 
and the cargo properties. The endocytosis pathways are typically classified into clathrin- and 
caveolae-mediated endocytosis, phagocytosis, macropinocytosis, and pinocytosis (Oh et al., 2014). 
Many types of cells use the clathrin- and caveolae-mediated endocytosis pathways to internalize 
nanoscale materials, including NPs.  
Clathrin- and caveolae-mediated endocytosis indicates receptor-mediated endocytosis. 
Macropinocytosis is a clathrin-, caveolin-, and dynamin-independent process that involves uptake 
of a larger volume of the membrane allowing particles of sizes ≈ 1 μm to be internalized. Similar to 
macropinocytosis, phagocytosis is also a clathrin-, caveolin-, and dynamin-independent process and 
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is proficient in internalizing larger particles including pathogens (Jiang W et al., 2008; Geiser M. 
2010). The physical size would not be fully reflected when they meet the plasma membrane of the 
cell. Most NPs tend to aggregate in biological solutions, increasing their overall size. Likewise, 
considering the possibility of the aggregation of NPs, the size of an aggregated nanocluster is larger 
than a single NP and will affect the internalization rate accordingly. The patterns of cellular uptake 
could also vary according to nanoparticle material type. 
Taking into account some results obtained by other authors NPs displayed non-specificity of 
endocytosis routes correlated with their mean diameter. In an in vitro study undertaken by Nicolete 
et al., PLGA microparticles (6.5 ± 3.9 μm) were still attached to the cell surface and required more 
time for endocytosis to occur. Simultaneously, PLGA NPs of size 389 nm (PDI =0.2) had already, 
within the same time period, been encapsulated in vesicles and endocytosed into the intracellular 
compartment (Nicolete R, et al., 2011). These results were consistent with the study conducted by 
Loh et al., which demonstrated poor internalization capability of chitosan particles that were 1 μm, 
much unlike the extensive uptake of NPs of sizes 110–390 nm (Loh JW, et al., 2012). Moreover, as 
demonstrated by Lu et al., it seems that the internalization of nanoparticles with a diameter less than 
200 nm involves clathrin-coated pits. With size increasing, a shift to a mechanism that relies on 
caveolae-mediated internalization becomes apparent, which becomes the predominant pathway of 
entry for particles of 500 nm in size (Lu F, et al., 2009). So, we could hypothesized that for both our 
type of NPs the same internalization mechanism occurred, related to the range of mean size. 
In addition to particle size, shape is another essential property of nanoparticles that plays important 
role in various biological processes and in vivo behavior. NPs shape shown to have a profound 
effect on the transport through the vasculature, circulation half-life, targeting efficiency, 
phagocytosis and endocytosis. It seems that the shape that contribute to phagocytosis inhibition and 
long circulation will, in turn, impede the endocytosis of NPs by the targeted cells (Duan et al., 
2013). 
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Both nanosuspensions, (NPA, NPBC3), are spherical, with smooth surfaces and rigid (not 
deformable). Non-spherical NPs show superior properties compared to spherical NPs in terms of 
escape from phagocytosis, long circulation half-life, and firm binding to the target tissues, however, 
the uptake of NPs significantly increase with increasing spherical morphology.  
Overall, this study demonstrates that nanoparticle charge is a crucial characteristic in terms of 
dictating their distribution and translocation in both rostral and/or caudal brain regions. Our in vivo 
experiments demonstrate that the fate of negative and positive NPs in neural cells was strictly 
correlated with their surface properties. Our data could not exclude the involvement of the systemic 
pathway. The localization of NPs in some brain sub-regions after 8 h suggested the occurrence of a 
probable direct N2B transfer. 
In fact, no PEGylated NPs are removed through a mononuclear phagocyte system (MPS) after 4/6 
hours of their presence in the body (Suk et al., 2016). Besides, NPs without suitable ligands on their 
surface are not able to cross the blood brain barrier (Tosi et al., 2016). 
At this point the question is: why did NPs arrive in the brain after a lag time, and different sub-
regions are involved? The answer is important not only to explain the potential application of 
nanocarriers but also the implication in the toxicological phenomenon of these colloidal carriers.  
First of all, to better understand our statements, it is important to introduce some results obtained by 
other authors in this field and the possible mechanisms involved. Some authors described the 
pathways and mechanism by which free molecules pass the nasal region to reach the brain if not 
absorbed via the systemic pathway and not drained by nasal lymphatic (Lockhead et al., 2012). 
There are two possibilities: the drug is transported to the brain encapsulated in the NPs through the 
neural or trans-epithelial pathways or the drug is released on the surface of the nasal epithelium or 
inside the tissue and then transported across the membrane (Mistry et al., 2009). Some experimental 
evidence demonstrated that the pathways involved nerves (olfactory and trigeminal) connecting the 
nasal passages to the brain and spinal cord (Dhuria et al., 2010). The nanoparticles could be taken 
up by the neuronal cells by processes of endocytosis, i.e., micropinocytosis or phagocytosis. Only 
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nanoparticles with a diameter smaller than 20 nm can achieve extracellular transport from the nasal 
cavity to the brain, only nanoparticles with diameter smaller of olfactory axons can be 
intracellularly transported to the bran via the olfactory neural pathway. We exclude the involvement 
of the extracellular pathway via tight junctions since the NPs were too large to pass through tissue 
using this route (Mistry et al., 2015).  
Analyzing our data, we could hypothesize that negative NPs arrived at the rostral sub-regions and 
then they were transported to caudal regions. This transport involved subcortical areas. Positive 
CS/PLGANPs were slower in transferring to the brain parenchyma than negative NPs and presented 
a prevalent localization in the caudal sub-regions. Two different pathways were used by the two 
types of NPs tested an intra-neuronal pathway for positive NPs, because the intra-neuronal pathway 
involves axonal transport and requires hours to days for drugs (and assumed nanoparticles) to reach 
brain regions. While the negative NPs may reach the brain areas through the extra-neuronal 
pathway, which probably relies on bulk flow transport through peri-neural channels that deliver 
drugs/particles directly to the brain parenchymal tissue and/or cerebral spinal fluid (CSF) (Chen et 
al., 2012). Therefore, we suggested that the surface differences between the nanocarriers tested, 
deeply influence the time course. In particular, we could affirm that chitosan enhanced the NPs 
residence time, due to electrostatic interactions and, at the same time for the same reason, it 
increased the time to reach the brain for NPs.  
The appearance of the fluorescence signal in rostral brain regions at early time points for negative 
NPs suggested the olfactory transport considering that the olfactory pathway may provide both 
intra-neuronal and extra-neuronal access to the brain (Hadaczek et al., 2006); on the contrary, the 
transport of positive NPs was different, since we found a weak fluorescent signal in all areas at 
early time points and a strong fluorescence intensity in caudal brain after 48h suggesting the 
involvement of the trigeminal nerve transport for positive NPs.  
Furthermore, the diameter and shape of these carrier system also play an essential for their cellular 
uptake.  
22 
 
Conclusion  
In this work nanotechnology systems and nose-to-brain delivery were investigated in order to 
provide new, patient-friendly solutions to delivering therapeutic agents to the brain. A specific ratio 
between PLGA and CS is needed to obtain a carrier having good stability at 25°C. Our data 
demonstrated that NPBC3 is the more suitable positive nanocarriers to perform in vivo study 
comparing its localization in respect to NPA (negative nanocarrier). Surface charge is a critical 
parameter to determine the site of localization of NPs. Our in vivo studies demonstrated that both 
NPs can reach the brain, even if the uptake of negative carriers seems prevalent in rostral sub-
regions, suggesting that NPA were possibly transported via olfactory pathway while NPBC3 seems 
to involve the trigeminal pathway. 
Our data also demonstrated differences in the localization of NPs in the brain areas dependent on 
the NPs physico-chemical properties in function at the time after IN administration. These findings 
raised the hypothesis that therapeutic agent loaded NPs may have a direct access to the CNS 
following IN administration.  
Not only NPs can reach the brain but it is possible to obtain a prevalent localization in caudal or 
rostral area depending on the NP surface charge. The results observed suggested that not only the 
mean size, as previously demonstrated by other authors (Mistry et al, 2015), is an important 
parameter but also the surface properties. On the basis of the neurological disease and in order to 
obtain a prevalent localization in the brain region affected, the accurate selection of the polymeric 
matrix to formulate nanocarriers is important for influencing surface charge.  
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Figure captions 
Graphical abstract: Schematic representation of rhodamine-labeled NPs distribution, 8, 24 and 
48h after IN administration in rat. Red spot indicates NPA; Blue-red spot indicates NPBC3. The 
intense, moderate and weak labeling correspond to large, medium and small spots respectively. The 
brain areas investigated are: cerebral cortex (beige); basal ganglia (light blue); hyppocampus 
(green); thalamus (pink); mesencephalon (orange); cerebellar cortex and nuclei (violet); 
myelencephalon (yellow). 
Figure 1. Mean size and polidispersitivity index of positive CS/PLGA nanoparticles obtained with a 
different amount of PLGA at an invariable amount of surfactant and chitosan. Values are presented 
as the mean ± S.D. (n = 3).  
Figure 2. Turbiscan Stability Index (A) as a function of an initial amount of PLGA polymer in 
positive CS/PLGA NPs at 25°C (-■- NPBC3; -▲- NPBC5; -●- NPBC10; -×- NPBC20); (B) Δ-
Backscattering (𝞓Bs) and Δ-Transmission(𝞓T) of NPBC3 at 25 °C. 
Figure 3. DSC Thermograms of A) NPBC3 (CS/PLGA NPs); B) NPA (PLGA NPs); C) PLGA; D) 
chitosan. 
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Figure 4. Physico-chemical and morphological properties of the rhodamine labeled nanocarriers 
(NPA and NPBC3) selected for in vivo studies. A) Scanning electron micrograph of NPBC3 
(CS/PLGA NPs); B) Scanning electron micrograph of NPA (PLGA NPs); C) Mean size and PDI of 
NPBC3 (CS/PLGA NPs); D) Mean size and PDI of NPA (PLGA NPs); E) Zeta potential of NPBC3 
(CS/PLGA NPs); F) Zeta potential of NPA (PLGA NPs). 
Figure 5. A) Photograph of rat brain not treated; B) Photograph of rat brain treated with rhodamine 
B solution; C) Photograph of rhodamine labeled PLGA NPs into cytosol of neural cells of the 
rostral region of the brain after IN administration (24 h). 
Figure 6. Photomicrographs illustrating the localization of the NPA (negative NPs) in relation to the 
brain sub-regions during the time-course (8, 24, 48 h) after IN administration. Rostro-caudal 
sequence of the brain sub-regions investigated: Frontal cortex (FC); Basal Ganglia (BG); 
Hippocampus (HPC); Mesencephalon (MES); Cerebellar nuclei (CN); Myelencephalon (MYE). 
The white narrow indicates the presence of rhodamine-labeled NPs. Scale bar=50 µm. 
Figure 7. Photomicrographs illustrating the localization of the NPBC3 (positive NPs) in relation to 
the brain sub-regions during time-course (8,24,48 h) after IN administration. Rostro-caudal 
sequence of the brain sub-regions investigated. Frontal cortex (FC); Basal Ganglia (BG); 
Hippocampus (HPC); Mesencephalon (MES); Cerebellar nuclei (CN); Myelencephalon (MYE). 
The white narrow indicates the presence of rhodamine-labeled NPs. Scale bar=50 µm. 
Supplementary data 
Figure 1. Release profile of rhodamine from negative and positive NPs in PBS pH 5.8 and pH 7.4 
at 37 °C until 48 h.  
Figure 2. Modified sagittal section of the rat brain according to Paxinos and Watson. 
 
 
